Research press release


Nature Medicine

Making tumors BRCAless



G Shapiroたちは、BRCA遺伝子の活性を調節する酵素を同時に阻害すれば、BRCA変異のないがん細胞であってもPARP阻害剤治療に対して感受性になることを明らかにした。この二重阻害法なら、BRCAの変異の有無にかかわらず、幅広くがんの治療に利用できる可能性がある。

A strategy to treat a broad range of cancers by focusing on the DNA repair process is published online this week in Nature Medicine. These findings could potentially expand the therapeutic range of inhibitors of PARP, a protein involved with DNA repair, which is currently used primarily to treat tumors resulting from BRCA gene mutations, to a broader range of cancers.

While promoting cancer, BRCA genetic alterations also debilitate the cancer cell’s ability to upkeep and repair its DNA. By further hampering this process, through targeting other essential components, such as PARP, selective killing of tumor cells can be achieved. However, this strategy can only be applied to BRCA mutation tumors.

Geoffrey Shapiro and colleagues show that simultaneous inhibition of an enzyme that regulates BRCA activity can make cancer cells without BRCA mutations sensitive to PARP inhibitor treatment. This dual inhibitor strategy could be generally applied to treating cancers regardless their BRCA mutational status.

doi: 10.1038/nm.2377


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。